Method of childbirth induction on gestation term 22-27 weeks in case of pouring out of amniotic fluid |
|
|
IPC classes for russian patent Method of childbirth induction on gestation term 22-27 weeks in case of pouring out of amniotic fluid (RU 2423973):
Method for prevention of retained placenta in cows / 2416417
Invention relates to veterinary science. The method involves rectal introduction of cooled sapropelic mud.
Method for prenatal preparation of full-term pregnant women with premature amenorrhea / 2408375
Invention refers to medicine, particularly to obstetrics, and concerns prenatal preparations of full-term pregnant women with premature amenorrhea. That is ensured by the administration of mifepristone 200 mg following amenorrhea immediately in a pregnant woman. The preparation is introduced once more in the same dosage 6 hours later.
 Method of managing poor uterine contraction strength / 2407534
Invention refers to medicine, particularly to obstetrics, and concerns managing primary uterine inertia (UI). The UI if observed requires amniotomy and intravenous jet introduction of 6% hydroxyethylated starch 500 ml regardless of the generative passage state. If 2 hours after intravenous infusion of starch, the UI is not normalised yet, intravenous introduction of oxytocics - enzaprost or oxytocin by a standard technique. If 4 hours later, the delivery is not terminated yet, intravenous jet introduction of 6% hydroxyethylated starch 500 ml is applied once again.
Method of birth complications prevention in women with contracted pelvis / 2403920
Invention refers to medicine, particularly to obstetrics, and concerns a method of birth complications prevention in women with contracted pelvis. For this purpose, 3-4 days prior to an estimated delivery date, oestradiol dipropionate 1.0 ml is introduced intramuscularly, while 10% calcium gluconate 10.0 ml and 5% ascorbic acid 4.0 ml are introduced intravenously. Prepidil gel is introduced in the cervical canal.
 Ethyl ether (±)-11,15-dideoxy-16-methyl-16-hydroxyprostaglandin e1 agent which exhibits uterotonic activity / 2394814
Invention relates to chemical and pharmaceutical industry and specifically to an agent which is ethyl ether (±)-11,15-dideoxy-16-methyl-16-hydroxyprostaglandin E1 of formula
Na mikhailova's method for augmentation of labour / 2380110
Invention refers to medicine, particularly to obstetrics and clinical pharmacology, and can be used for augmentation of uterine contractions with oxytocin solution in full-term pregnancy. An oxytocin dose is pre-calculated from the relation DDR. = 1IU M·/80, where DDR. is a required dose of oxytocin in IU, M is a digital expression of weight of a parturient woman, kg. Oxytocin is dissolved in 300-500 ml of 0.9% sodium chloride. In the absence of labour activity, the preparation is introduced continuously, starting with 1 drop a minute and once-a-minute increasing introduction rate 1 to more drops to the first uterine contractions. The effective introduction rate is calculated, and the preparation is introduced during periods of uterine relaxation. The insufficient labour activity requires a single dose increased in 1.5 times. In overdosing, introduction of oxytocin solution is stopped with immediately venous infusion of 0.9% sodium chloride.
 Method for arrest of metrorrhagia and device for arrest of metrorrhagia / 2347589
Hemostatics and uterotonic agents are parenterally introduced. Previously folded intrauterine rubber balloon catheter with delivery and support in the form of tubular element rounded at distal end with length that is comparable to but not less than total length of uterine cavity and vagina is introduced into cavity of birth canal. Irrigation and drain tubes from elastic shape-holding material are located on external surface of balloon. Length of tubes exceeds length of tubular element for delivery and support of balloon catheter with possibility of exit beyond the limits of birth canal - from vagina. Distal ends of tubes are rounded with openings on the surface for contents outlet and collection. One of tubes is arranged with the possibility of connection with syringe for introduction of hemostatic into uterine cavity, other tubes are connected with reservoir for collection of drained liquid. Tubular element for delivery and support of balloon catheter is connected with reservoir for filling of balloon catheter with sterile liquid, the second tube installed in reservoir above liquid level is connected to manometer, and pump for pressure charging is located at its end. This device is located from entry to vagina to uterus bottom, fixing proximal end of balloon catheter with tubes in entry to vagina. Then sterile physiological solution is pumped into catheter by means of pump until visually controlled bleeding is arrested. After bleeding has been stopped, pressure value is fixed, then pressure changes are registered in filled balloon catheter, at that pressure rise is treated as restoration of uterus contractive activity, afterwards pulled pressure is reduced in successive steps down to fixed value. If pressure value in catheter drops, it is increased up to fixed value. In both cases fixed pressure of bleeding arrest is maintained for at least 30 minutes, reduction is carried out in successive steps by 10 mm of mercury column every 5-10 minutes. Hemostatics are introduced into uterine cavity by irrigation tube in appropriate doses, then all tubes are isolated for the time sufficient for creation of blood clot. If no bleeding takes place through drain tubes in process of stepwise pressure reduction, pressure is dropped, liquid is removed from balloon catheter, and it is withdrawn outside.
 Benzamide derivatives as oxytocin agonists and vasopressin antagonists / 2340617
Novel compounds are selected from group, consisting of: 4-(2-cyclopropyl-ethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopropylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopropylmethyl-piperazine-1-carboxylic acid 3-fluorine-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-(2-hydroxymethyl-cyclopropylmethyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopentylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopropylmethyl-piperazine-1-carboxylic acid 3-chlorine-4-(3-methyl- 4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 3-chlorine-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-(2-cyclopropyl-ethyl)-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 3-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 3-fluorine-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 2-fluorine-4-(3-methyl-4,10-dihudro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopropylmethyl-piperazine-1-carboxylic acid 2-fluorine-4-(3-methyl-4,10-dihydro-3H-2,3,4;9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopropylmethyl-piperazine-1-carboxylic acid 3-ethyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclobutylmethyl-piperazine-1-carboxylic acid 2-chlorine-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide; 4-cyclopropylmethyl-piperazine-1-carboxylic acid 2-chlorine-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide and 4-cyclobutylmethyl-piperazine-1-carboxylic acid 3-methoxy-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraazabenzo[f]azulene-9-carbonyl)-benzylamide. Invention also relates to pharmaceutical composition and to application of compounds of general formula 1.
Method of medicamental induction of act of delivery / 2338539
Preliminary count a dose of gel of dinoprostonum from a parity V med. = 2.5 ml · M/70, where V med. - necessary volume of gel, and M - digital expression of mass of a body of the parturient woman in kg. Warm up gel to a body temperature. By means of ultrasound visualise a vagina locating in space, place and fix a body of the parturient woman so that the posterior vaginal vault has appeared its bottom part. At weakening of retractive activity of a uterus carry out administration of preliminary calculated quantity of gel. At an overdosage into a vein enter an infusional solution, delete gel by a vagina lavage the solution of 0.9% sodium chloridum warmed up to a body temperature to "pure water" then place the body in position at which the entrance of vagina appears the lowermost part of a vagina.
 Derivatives of 1-n-phenylamino-1h-imidazole and pharmaceutical compositions containing them / 2327691
Imidazole derivatives have general formula (I)
Method of choosing therapeutic approach in menstrual disorders in adolescent girls with overweight / 2422824
In adolescent female patients with overweight suffering menstrual disorders of oligomenorrhea or amenorrhea type are examined for a body weight index (BWI) and blood serum leptin level measured by enzyme immunoassay. And if the BWI of the patient exceeds 25.0 kg/m2, and the leptin level is less than 32.52 ng/ml, diet therapy and graduated physical activity are prescribed. The leptin level 32.52 ng/ml and higher in the patient requires additional glucose tolerance test to a common technique to detect insulin resistance. If observing insulin resistance, the complex treatment includes the preparations to provide higher peripheral tissue sensitivity (sensitisers) to insulin. The absence of insulin resistance enables to prescribe the therapy of combined oral contraceptives with drospirenone.
Method for prenatal preparation of full-term pregnant women with premature amenorrhea / 2408375
Invention refers to medicine, particularly to obstetrics, and concerns prenatal preparations of full-term pregnant women with premature amenorrhea. That is ensured by the administration of mifepristone 200 mg following amenorrhea immediately in a pregnant woman. The preparation is introduced once more in the same dosage 6 hours later.
 Method of rectal cancer treatment / 2387470
Testosterone is introduced intramuscularly and applied on the stomach and breast skin to ensure the steady high blood concentration. 6-8 hours prior to a session of gamma-ray teletherapy, a composite is introduced through rectum. The composite contains sodium alginate, dimethyl sulphoxide solution and testosterone. 6-8 hours later, the composite is removed from rectum. It is followed with gamma-ray teletherapy with "РОД" 5 Gy and local microwave hyperthermia.
Composition containing combination of aromatase inhibitor, progestin and estrogen, and its application for endometriosis treatment / 2360681
Invention refers to medicine, namely to gynaecology and represents the combination for preparing the medical product, containing Anastrozol, Levonorgestrel and Ethynyl Estradiol, the pharmaceutical composition for endometriosis treatment containing Anastrozol, Levonorgestrel and Ethynyl Estradiol and endometriosis treatment method that involves introduction of Anastrozol, Levonorgestrel and Ethynyl Estradiol.
 Oral contraceptives for prevention pregnancy and reduction of premenstrual symptomatology / 2351339
Invention distinguishes 28-day and 91-day modes of taking combined oral contraceptives, possibly in combination with antidepressant (fluoxetine hydrochloride) in which full disappearance of estrogen from preparation does not take place. This presupposes that shorter influence of peaks and drops of endogenic progesterone protects against premenstrual disphoric disorder (PMDD) and against symptoms of mood disturbance in women with PMS.
Method of puberty metrorrhagia treatment / 2327462
Hormonal haemostasis is performed using complex oral contraceptive (COC) in dosage 1/2 tablet COC every 4-6 hours until metrorrhagia stops, and as well as during 1st day after. Further daily dose is reduced by 1/2 tablet every for next day. Whereas dosage 1 tablet a day is achieved, COC introduction is prolonged for another 21 days. After that within 3 months cerebrum compositum combined with coenzyme compositum dosed 2.2 ml is intramuscularly injected. Introduction of these agents is alternated with mixed cerebrum compositum and ubiquinone compositum injections dosed 2.2 ml. this therapy is combined with peroral introduction of lymphomyosote and nux vomyka-homaccord in dosage 10 drops 3 times a day, as well as hepel and neurohel dosed 1 tablet a day.
 Method of complex treatment of polypous rhinosinusitis in patients with bronchial asthma / 2324511
Low-intensity laser with wave 630 nm and power 50 mcW/cm2 is applied daily with course of 15 days. For external application: the nose bridge is exposed for 1 min, central part of dorsum of nose - for 20 sec, in point of fossa canina on both sides - for 1 min. Intranasal application - the light guide is inserted 1 cm into both nasal meati alternately, exposure time - 15 sec. Blood is exposed transcutaneously by 15 min exposure of the area above the ulnar vena. Simultaneously with the laser therapy course, the patient is administered intranasally the combined inhaler Seretid, which contains Salmeterol (25 mcg) and Fluticazone propionate (125 mcg), during inspiration, into each nasal meatus, twice a day.
Surgical method for treating tubal pregnancy cases / 2299069
Method involves determining chorionic gonadotropin concentration in blood in progressing tubal pregnancy cases during 5 weeks before operation. Chorionic gonadotropin concentration being below 500 IU/l, 100 mg of Mifepriston are to be introduced at the first and third preoperative preparation day. Fetal ovum removal is carried out at the fifth-seventh day from the beginning of preoperative preparation. Chorionic gonadotropin concentration being from 500 IU/l to 2000 IU/l, 200 mg of Mifepriston are to be introduced at the first and third preoperative preparation day. Fetal ovum removal is carried out at the fifth day from the beginning of preoperative preparation. Chorionic gonadotropin concentration being greater than 2000 IU/l, 200 mg of Mifepriston are to be introduced at the first, third and sixth preoperative preparation day. Fetal ovum removal is carried out at the eighth-tenth day from the beginning of preoperative preparation.
 17α-alkyl-17β-hydroxyestratrienes, their using and pharmaceutical preparation / 2285009
Invention describes 17α-alkyl-17β-hydroxyestra-1,3,5(10)-trienes possessing anti-estrogenic properties of the general formula (I):
 Formulated with contraceptive activity / 2238095
The invention relates to medicine, in particular to hormonal tools, and comes with contraceptive activity gestagen-estrogenic composition
Suppositories for treating proctologic and gynecologic diseases / 2421210
Invention refers to suppositories for treating proctologic and gynaecologic diseases. Said suppositories contain a drug in the form of the dehydrated preparation 'Baliz' or a power-predried form of the preparation 'Baliz', or an active substance pre-recovered from the preparation 'Baliz' in the form of comenic acid or its salts, and also a base representing fatty substances, and a food or medicinal emulsifier.
|
FIELD: medicine. SUBSTANCE: invention relates to medicine, and namely to obstetrics and gynecology, and can be applied for induction of childbirth. For this purpose per orally mifepristone is taken on first day in dose 200 mg three times after every 4 hours. One day after first intake of mifepristone in back fornix of vagina introduced is dinoproston 1 mg. EFFECT: method insures preparation of neck of uterus to childbirth, independent delivery without complications in childbirth in case of premature pregnancy in early terms and premature pouring out of amniotic fluid. 1 ex
The invention relates to medicine, namely to the field of labor induction of premature rupture of amniotic fluid and premature pregnancy, and can be used in the practice of obstetrics. There is a method of preparation of the cervix for childbirth at term and advanced pregnancy the use of osmotic straddling of kelp, which are entered endovaginal 6-12 hours for subsequent labor induction (Lvhuitou, Vasilovich / the Use of kelp for the preparation of the cervix for childbirth // Obstetrics and gynecology. - 2006. No. 5. P.47 - 49). The disadvantage of this method is that kelp prolonged their stay in the cervical canal increase the risk of ascending infection and do not apply when premature rupture of amniotic fluid. Also known the way of labor activation with the use of prostaglandin E1 misoprostol (Gwillimbury. The efficacy and safety of labor activation with the use of prostaglandin E1. The urgency of the problem // proceedings of the IV Congress of obstetricians and gynecologists Russia. - M., 2008 - P.28-29). However, at the present time in Russia, the use of misoprostol in pregnant women is prohibited due to the high frequency of complications, such as tehnicheskie reduction and hypertonicity of the uterus, distress fruit. Closest to the claimed object is the preparation shake the uterus for childbirth at term of pregnancy with mifepristone at a dose of 200 mg once a day orally for 2 days (Isidorov, Arguablely / the Effectiveness of various methods of preparation of the cervix for childbirth when postmaturity // ROS. Bulletin of the obstetrician-gynecologist. - 2004. No. 6. - Pp.62-64). The disadvantage of this method is too long to prepare "maturity" of the cervix (within 2 days). This method is recommended for full-term pregnancy and when perenashivanie and not advisable in case of premature pregnancy and premature rupture of amniotic fluid. The method does not cause the development of independent labor activity, but only prepares the cervix for childbirth. At the same time, there are situations when you need quick preparation of the cervix to delivery, in particular when premature rupture of amniotic fluid and the periods of gestation 22-27 weeks, especially in combination with high risk of infectious complications. The objective of the invention is the provision of cervical preparation for delivery and labor induction of premature rupture of amniotic fluid and the periods of gestation 22-27 weeks. The problem is solved in that in the method of induction to delivery, including acceptance of oral mifepristone, mifepristone on the first day administered 200 mg orally three times every 4 hours through the day after the first dose of mifepristone in the posterior vaginal vault enter dinoprostone 1 mg The method is as follows: when the m of mifepristone on the first day administered 200 mg orally three times every 4 hours, a day after the first dose of mifepristone in the posterior vaginal vault enter dinoprostone 1 mg Example. Conducted preparation of the cervix for childbirth and their induction of 35 patients with gestation periods 22-27 weeks and premature rupture of amniotic fluid. The cervix in all patients was "immature" on a scale of Bishop. The preparation was carried out as follows: mifepristone 200 mg orally, repeated administration of mifepristone 200 mg every 4 h, and the third mifepristone 200 mg after 4 o'clock the next day after the first dose of mifepristone appoint dinoprostone 1 mg, which is injected in the posterior vaginal vault. During the second day after the beginning of the preparation of the cervix for childbirth independently odoratissimus 29 patients (82.9 per cent), at the beginning of the third - 6 (17,1%). Complications in childbirth was not observed. The method of induction to delivery, including mifepristone, oral, characterized in that the mifepristone on the first day administered 200 mg orally three times every 4 hours through the day after the first dose of mifepristone in the posterior vaginal vault enter dinoprostone 1 mg
|